CoreCap Advisors
PVLA icon

CoreCap Advisors’s Palvella Therapeutics PVLA Stock Holding History

CoreCap Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.52K Hold
11
– – ﹤0.01% 2577
2026
Q2 		$1.68K Buy
+11
New +$1.34K ﹤0.01% 2587

Other funds holding PVLA

Clio Asset Management
Clio Asset Management Charlottesville, Virginia $119M AUM 1.1% 1-Year Est. Return
Aspiriant LLC
Aspiriant LLC Los Angeles, California $4.08B AUM 12.02% 1-Year Est. Return
Avior Wealth Management
Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Private Trust Company
Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Physician Wealth Advisors
Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

CoreCap Advisors's PVLA Position: Q3 2026 in Review

CoreCap Advisors held its Palvella Therapeutics (PVLA) position steady in Q3 2026 at 11 shares worth $1.52K. The position accounts for ﹤0.01% of the portfolio, ranked #2577.

CoreCap Advisors first reported a position in PVLA in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.68K in Q2 2026. 16 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • CoreCap Advisors held 11 shares of Palvella Therapeutics worth $1.52K as of Q3 2026.
  • CoreCap Advisors left its Palvella Therapeutics share count unchanged in Q3 2026.
  • Palvella Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2577 holding.
  • CoreCap Advisors first reported a position in Palvella Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • CoreCap Advisors's Palvella Therapeutics position peaked at $1.68K in Q2 2026.
  • 16 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.